Clients

• Angiogenix
  Collabrity prepared financial plan and presentation for Series D financing.
• Applied Genetic Technologies Corporation (AGTC)
  Collabrity led efforts to negotiate and close corporate partnership with Genzyme. Other deals completed: MedImmune, University of Alabama.
• Aryx
  Collabrity performed valuation of GI asset, subsequently licensed to P&G Pharma.
• Celladon
  Collabrity provided ongoing support, analysis and advice concerning option-to-acquire negotiation with large pharma.
• Eli Lilly, Chorus division
  Collabrity developed business case for proposed spin-out of company.
• Enterprise Partners Venture Capital
  Collabrity delivered comprehensive valuation of portfolio company’s gene therapy for heart failure.
• Exelixis
  Collabrity assessed combinatorial chemistry partnering opportunity.
• Genencor
  Collabrity led business planning for novel biofuels product.
• Genentech
  Collabrity performed benchmarking analysis on ten deals.
• MaxCyte
  Collabrity conducted out-licensing efforts for novel oncology cell therapy.
• NeurAxon
  Collabrity helped coach the CEO for board presentation evaluating deal landscape for a novel CNS therapy.
• Nuvelo
  Collabrity led campaigns to partner clinical platform with > $1 B peak sales potential in Inflammation / Oncology and to partner preclinical stage cancer antibodies.
• PDxRx
  A startup pediatric pharma company that raised $1 million.  Collabrity advisors served in CEO and Head of Business Development roles and negotiated key terms agreements on three product in-license deals.
• Synamem
  Collabrity prepared business plan for private investor financing.
• Zymetis
  Collabrity coached CEO in preparation for key terms negotiation on company's first cellulosic ethanol biorefinery.